BofA raises UnitedHealth stock price target on strong earnings beat By Investing.com

UnitedHealth reported Q1 adjusted EPS of $7.23, beating consensus by $0.70, and raised 2026 EPS guidance by $0.50 to $18.25. The beat was helped by a medical loss ratio of 83.9%, 190bps below consensus, though higher operating expense and AI investments partially offset the upside. BofA lifted its price target to $371 from $337 while keeping a Neutral rating, citing pending visibility on Stars ratings and the 2028 Medicare Advantage rate notice.

Analysis

The market is rewarding an earnings reset, but the important signal is not the quarter itself — it’s the implied de-risking of 2026–2027 earnings after a period when investors had started to price in a structural margin problem. In managed care, a one-quarter medical cost beat is usually less important than whether pricing and utilization now look aligned; if they do, the multiple can re-rate quickly because the downside case was built on compounding margin erosion. That said, the spread between the higher target and the stock’s current multiple suggests the Street is still treating the name as a “show me” story rather than a clean recovery.

The second-order winner is the broader managed care complex, but only selectively. If UnitedHealth can defend margins while continuing to spend on AI and operations, it raises the bar for peers that lack scale in data/administrative automation; smaller insurers with weaker procurement and care-management leverage may need to sacrifice growth or margin. The risk is that this quarter encourages complacency just as Medicare-related visibility remains the main variable that can change the earnings slope over the next 6–12 months.

Contrarian angle: the crowd may be over-indexing on the EPS raise and underweighting the quality of the mix. If the earnings improvement is heavily cost- and timing-driven rather than durable utilization control, the stock can stall even with a higher target. Conversely, if the 2028 reimbursement framework proves less punitive than feared, the current valuation could still be too cheap for a business with persistent capital returns and high conversion of earnings into cash over multi-year horizons.

Key Decisions for Investors

• Go long UNH on any 2–3% pullback over the next 1–2 weeks; target a move toward the new valuation anchor over 3–6 months, with a stop if the stock gives back the post-print gap and fails to hold the prior breakout level.
• Buy UNH call spreads 3–6 months out to express upside with defined downside; structure around the thesis that multiple compression should ease if follow-through commentary confirms margin durability.
• Pair trade: long UNH / short a weaker large-cap managed care peer over 1–2 quarters to isolate execution quality and scale advantages; the spread should benefit if investors reward visible earnings stability rather than balance-sheet optionality.
• Avoid chasing after the initial move if the stock trades above the implied fair-value band without additional visibility on reimbursement; upside is better expressed via options than outright size at this stage.
• Watch the next catalyst window around regulatory updates and commentary on Stars/Medicare pricing; if that visibility improves, add to the long, but if it deteriorates, de-rate the trade quickly because the thesis is regulatory, not cyclical.